Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | PPARD | Q03181 | 1/20 | 0.50 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.50 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.50 |
| ▸ | ZDHHC7 | Q9NXF8 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 8/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.37 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.37 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.37 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10001215 | 0.92 | LCK (0.62) | LCKPPARDZDHHC20ZDHHC2ZDHHC7 | |
| SCHEMBL8463182 | 0.77 | CA2 (0.46) | CA2MAPK1CA1SLC1A3SLC1A2 | |
| SCHEMBL1778121 | 0.77 | ALDH1A1 (0.39) | LCKPPARDZDHHC20ZDHHC2CA2 | |
| SCHEMBL8997427 | 0.77 | LCK (0.58) | LCKPPARDZDHHC20ZDHHC2ZDHHC7 | |
| SCHEMBL14519745 | 0.76 | CA1 (0.48) | CA2MAPK1CA1SLC1A3SLC1A2 | |
| SCHEMBL10001196 | 0.76 | CA2 (0.61) | CA2MAPK1CA1SLC1A3SLC1A2 | |
| SCHEMBL931024 | 0.75 | — | — | |
| SCHEMBL140785 | 0.75 | — | — | |
| SCHEMBL5615305 | 0.75 | — | — | |
| SCHEMBL1449048 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093427-B2 | Construction and screening of solution-phase derived library of fenbufen and ethacrynic acid | NATIONAL TSING HUA UNIVERSITY (TW) | 2012-01-10 | — | — | US | disclosed |
| US-20110306668-A1 | CONSTRUCTION AND SCREENING OF SOLUTION-PHASE DERIVED LIBRARY OF FENBUFEN AND ETHACRYNIC ACID | NATIONAL TSING HUA UNIVERSITY (TW) | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306668-A1 | CONSTRUCTION AND SCREENING OF SOLUTION-PHASE DERIVED LIBRARY OF FENBUFEN AND ETHACRYNIC ACID | CYP4F2, ACR, CYP4F3 | LCK 3178/4885PPARD 2530/4885ZDHHC20 1130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.